Redefining hydrophilic coatings solutions by uniting advanced chemistry, device engineering and customer-first partnerships BEVERLY, Mass.–(BUSINESS WIRE)–#FreudenbergRedefining hydrophilic coatings solutions by uniting advanced chemistry, device engineering and customer-first partnerships BEVERLY, Mass.–(BUSINESS WIRE)–#Freudenberg

Freudenberg Medical Ushers in a New Era for Hydrophilic Coatings with Launch of LUBRITEQ™

5 min read

Redefining hydrophilic coatings solutions by uniting advanced chemistry, device engineering and customer-first partnerships

BEVERLY, Mass.–(BUSINESS WIRE)–#Freudenberg—Freudenberg Medical, a global contract design and manufacturing (CDMO) partner to the medical device and biopharma industry, today announced the launch of LUBRITEQ™, a new high-performance hydrophilic coating solution, along with a comprehensive suite of associated development and manufacturing services. LUBRITEQ™ is now available globally across Freudenberg Medical’s vertically integrated operations.

With the launch of LUBRITEQ™, Freudenberg Medical becomes the only hydrophilic coating provider to unite advanced surface chemistry with deep, in-house medical device design and manufacturing capabilities—bringing together complementary technologies to enhance manufacturability and deliver greater productivity and reliability across the entire product development lifecycle.

“Hydrophilic coatings and device design must work in perfect harmony to deliver optimal performance, yet the industry has traditionally approached them as separate disciplines,” said Michael McGee, CEO of Freudenberg Medical. “As a uniquely integrated technical partner, we enable customers to move faster, with less risk and greater confidence, by combining product design, advanced materials, precision coatings, and application expertise for seamless development, scale-up, and launch.”

Built on a Deep Expertise in Surface Chemistry

Freudenberg Medical brings more than 25 years of experience in coating science, supported by a proven legacy of innovation, including expertise integrated through Hemoteq, that has enabled customers to achieve multiple industry firsts in complex drug-device and surface modification solutions.

“With more than 40 coating scientists, chemical engineers and technicians working alongside 250 medical device & catheter engineers globally, we have unparalleled expertise in developing complex chemistry and drug-device solutions for our customers,” said McGee. “We already support over one million medical devices each year for functional surface coatings, making the introduction of LUBRITEQ™, our hydrophilic coating solution, a natural evolution and logical next step aligned with our customers’ needs.”

Shaped by Customer Needs

Freudenberg Medical’s decision to enter the hydrophilic coatings market was guided by extensive engagement with customers and industry stakeholders to understand where existing solutions and partnerships can be improved, and where unmet needs continue to exist. Through these exchanges, it became clear that while coating technologies have advanced, customer needs are not being fully served—particularly when it comes to the flexibility of support services and complexities of royalties, licenses and fees.

“We heard consistent feedback that directly shaped our strategy,” said Freudenberg Medical’s Chief Commercial Officer, Keith Kiernan. “Customers aren’t just looking for a better coating—they’re looking for a better partner to de-risk their product launches. We deliberately set out to deliver a solution—and a partnership model—that reflects exactly what customers told us they need. No royalties, no rigidity—just coating performance, partnership and progress.”

Introducing LUBRITEQ™ Hydrophilic Coating & Services

LUBRITEQ™ is an advanced, UV-curable, single-step hydrophilic coating engineered for versatility and performance across a wide range of medical device applications and polymer & metal substrates. The coating delivers high lubricity with exceptional durability, consistent uniformity and ultra-low particulates. LUBRITEQ™ is customizable to optimize performance for specific device requirements and is compatible with virtually all approved materials used in medical device designs.

Recognizing that coating performance alone is not enough, Freudenberg Medical is launching LUBRITEQ™ alongside a comprehensive services model that supports customers across the full product lifecycle—from early feasibility through commercial production. Services include a rapid two-week first feasibility turnaround, tailored coating customization programs, and flexible volume-manufacturing options, including process transfer to the customer or contract coating support across Freudenberg Medical’s global site network. This integrated approach eliminates hand-offs across multiple suppliers, reducing risk and accelerating product development timelines.

Customer-First and Transparent, Commercial Model

In contrast to traditional industry practices, Freudenberg Medical is introducing a straightforward and transparent commercial model for LUBRITEQ™, designed to eliminate hidden costs and reduce program launch risk. Customers can access a high-performance hydrophilic coating solution with no royalties, no fixed or annual fees, and no regulatory file access fees.

Together, these elements remove commercial barriers and enable long-term, trust-based partnerships.

“With LUBRITEQ™, Freudenberg Medical is raising the bar for what a hydrophilic coating partner can and should be,” said CEO Michael McGee. “The early responses we’re seeing from customers confirm that we’re meeting a real need. Great technology, great service and a commercial model built on trust—that’s the standard we are setting.”

Freudenberg Medical is launching LUBRITEQ™ at MD&M West. Visit Booth 2609 to learn more about LUBRITEQ™ and discover how Freudenberg Medical is redefining what’s possible in hydrophilic coatings. Visit LUBRITEQ™ for more information.

About Freudenberg Medical

Freudenberg Medical is a trusted strategic CDMO partner to medical device and pharmaceutical companies, committed to delivering high-quality solutions from ideation to market launch and volume production. With over 2,900 associates across 12 global manufacturing sites in key MedTech hubs and proven expertise in materials and technologies, Freudenberg Medical offers an extensive range of vertically integrated capabilities: from minimally invasive solutions including complex catheters, hypotubes, steerable shafts, handles as well as drug and hydrophilic coatings to precision molding, two-shot and micro molding, advanced extrusions, and solutions for smart medical devices. www.freudenbergmedical.com

Contacts

Media Contacts
Laura Kirstein
Director Marketing and Communications
Freudenberg Medical
laura.kirstein@freudenbergmedical.com

Maura Leahy
Strategic Marketing
Freudenberg Medical
maura.leahy@freudenbergmedical.com

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Botanix launches stBTC to deliver Bitcoin-native yield

Botanix launches stBTC to deliver Bitcoin-native yield

The post Botanix launches stBTC to deliver Bitcoin-native yield appeared on BitcoinEthereumNews.com. Botanix Labs has launched stBTC, a liquid staking token designed to turn Bitcoin into a yield-bearing asset by redistributing network gas fees directly to users. The protocol will begin yield accrual later this week, with its Genesis Vault scheduled to open on Sept. 25, capped at 50 BTC. The initiative marks one of the first attempts to generate Bitcoin-native yield without relying on inflationary token models or centralized custodians. stBTC works by allowing users to deposit Bitcoin into Botanix’s permissionless smart contract, receiving stBTC tokens that represent their share of the staking vault. As transactions occur, 50% of Botanix network gas fees, paid in BTC, flow back to stBTC holders. Over time, the value of stBTC increases relative to BTC, enabling users to redeem their original deposit plus yield. Botanix estimates early returns could reach 20–50% annually before stabilizing around 6–8%, a level similar to Ethereum staking but fully denominated in Bitcoin. Botanix says that security audits have been completed by Spearbit and Sigma Prime, and the protocol is built on the EIP-4626 vault standard, which also underpins Ethereum-based staking products. The company’s Spiderchain architecture, operated by 16 independent entities including Galaxy, Alchemy, and Fireblocks, secures the network. If adoption grows, Botanix argues the system could make Bitcoin a productive, composable asset for decentralized finance, while reinforcing network consensus. This is a developing story. This article was generated with the assistance of AI and reviewed by editor Jeffrey Albus before publication. Get the news in your inbox. Explore Blockworks newsletters: Source: https://blockworks.co/news/botanix-launches-stbtc
Share
BitcoinEthereumNews2025/09/18 02:37
PBOC sets USD/CNY reference rate at 6.9590 vs. 6.9570 previous

PBOC sets USD/CNY reference rate at 6.9590 vs. 6.9570 previous

The post PBOC sets USD/CNY reference rate at 6.9590 vs. 6.9570 previous appeared on BitcoinEthereumNews.com. On Friday, the People’s Bank of China (PBOC) sets the
Share
BitcoinEthereumNews2026/02/06 09:28
UK and US Seal $42 Billion Tech Pact Driving AI and Energy Future

UK and US Seal $42 Billion Tech Pact Driving AI and Energy Future

The post UK and US Seal $42 Billion Tech Pact Driving AI and Energy Future appeared on BitcoinEthereumNews.com. Key Highlights Microsoft and Google pledge billions as part of UK US tech partnership Nvidia to deploy 120,000 GPUs with British firm Nscale in Project Stargate Deal positions UK as an innovation hub rivaling global tech powers UK and US Seal $42 Billion Tech Pact Driving AI and Energy Future The UK and the US have signed a “Technological Prosperity Agreement” that paves the way for joint projects in artificial intelligence, quantum computing, and nuclear energy, according to Reuters. Donald Trump and King Charles review the guard of honour at Windsor Castle, 17 September 2025. Image: Kirsty Wigglesworth/Reuters The agreement was unveiled ahead of U.S. President Donald Trump’s second state visit to the UK, marking a historic moment in transatlantic technology cooperation. Billions Flow Into the UK Tech Sector As part of the deal, major American corporations pledged to invest $42 billion in the UK. Microsoft leads with a $30 billion investment to expand cloud and AI infrastructure, including the construction of a new supercomputer in Loughton. Nvidia will deploy 120,000 GPUs, including up to 60,000 Grace Blackwell Ultra chips—in partnership with the British company Nscale as part of Project Stargate. Google is contributing $6.8 billion to build a data center in Waltham Cross and expand DeepMind research. Other companies are joining as well. CoreWeave announced a $3.4 billion investment in data centers, while Salesforce, Scale AI, BlackRock, Oracle, and AWS confirmed additional investments ranging from hundreds of millions to several billion dollars. UK Positions Itself as a Global Innovation Hub British Prime Minister Keir Starmer said the deal could impact millions of lives across the Atlantic. He stressed that the UK aims to position itself as an investment hub with lighter regulations than the European Union. Nvidia spokesman David Hogan noted the significance of the agreement, saying it would…
Share
BitcoinEthereumNews2025/09/18 02:22